In severe pseudo‑exfoliation (PEX) glaucoma, should selective laser trabeculoplasty (SLT) be performed, and what are the recommended laser parameters and subsequent medical management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

SLT in Severe PEX Glaucoma: Proceed with Caution but Consider as Adjunctive Therapy

In severe pseudoexfoliation (PEX) glaucoma, SLT can be performed as an adjunctive treatment to medical therapy, but should not replace aggressive medical management or delay filtration surgery when indicated, given the typically aggressive nature of severe PEX glaucoma and the need for substantial IOP reduction to prevent vision loss.

Clinical Context and Decision Framework

Severe PEX glaucoma presents a unique challenge because these eyes require aggressive IOP lowering to prevent progression. While the AAO Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines 1 discuss laser trabeculoplasty primarily in the context of POAG, the evidence specific to PEX glaucoma shows both promise and limitations.

When to Consider SLT in Severe PEX Glaucoma

Appropriate scenarios:

  • As adjunctive therapy when medical therapy alone is insufficient but patient is not yet ready for or refuses filtration surgery
  • In patients with medication adherence issues who cannot reliably use multiple topical agents 1
  • As a temporizing measure while optimizing the patient for incisional surgery
  • In medically uncontrolled cases where additional IOP reduction of 20-30% would achieve target pressure

When to avoid SLT and proceed directly to surgery:

  • Advanced visual field loss with high risk of progression
  • Very high baseline IOP (>30 mmHg) requiring immediate substantial reduction
  • Evidence of rapid progression despite maximal medical therapy
  • When target IOP requires >40-50% reduction from baseline

Evidence-Specific to PEX Glaucoma

The most recent studies demonstrate that SLT achieves meaningful IOP reduction in PEX glaucoma, with success rates of 42-85% at one year 2, 3. Specifically:

  • A 2026 prospective study showed 85% success rate with 31% mean IOP reduction at 12 months in PEXG patients 2
  • Another 2026 study demonstrated 19.8% IOP reduction at 6 months using the VISULAS green laser 4
  • Korean patients with medically uncontrolled PEXG showed 41.9% success rate at 12 months, with mean IOP reduction of 39.3% in responders 3

Critical caveat: The heavily pigmented trabecular meshwork characteristic of PEX glaucoma increases the risk of IOP spikes (4.5-27% of cases) 1. This is particularly concerning in severe glaucoma where even transient IOP elevation can cause further optic nerve damage.

Recommended Laser Parameters

Standard SLT technique for PEX glaucoma:

  • Laser: 532 nm Q-switched frequency-doubled Nd:YAG laser 1
  • Treatment extent: 360-degree treatment is preferable, as 180-degree treatment shows inferior results compared to medical therapy 1
  • Energy settings: Start conservatively given heavy pigmentation; titrate to achieve visible "champagne bubble" reaction
  • Spot size/duration: Standard 400 μm spot, 3 nanosecond pulse duration

Perioperative Management

Mandatory pre-procedure steps 1:

  • Obtain informed consent discussing risks including IOP spikes, need for additional surgery
  • Baseline IOP measurement immediately before procedure
  • Consider prophylactic IOP-lowering medication (brimonidine or apraclonidine) given high spike risk in pigmented meshwork 1

Post-procedure monitoring 1:

  • Critical: IOP check within 30 minutes to 2 hours post-procedure 1
  • IOP spikes >5 mmHg occur in up to 20% of PEX cases 4 and must be treated immediately in severe glaucoma
  • Follow-up within 1 week, then at 1,3,6, and 12 months
  • Continue all baseline glaucoma medications unchanged initially

Expected adverse effects 2, 5:

  • Mild anterior chamber inflammation (32.5% of cases) - typically self-limited
  • Conjunctival redness (67% in one series) - resolves within days
  • Transient IOP elevation - more common than in POAG due to heavy pigmentation

Subsequent Medical Management

After SLT, maintain aggressive medical therapy:

  • Do not reduce medications based on SLT alone; wait for documented sustained IOP reduction over 4-6 weeks
  • Continue maximal tolerated medical therapy, particularly prostaglandin analogs which show comparable efficacy to SLT 1
  • Consider medication reduction only if IOP remains at or below target for 2-3 consecutive visits

If SLT fails or provides insufficient reduction:

  • In severe glaucoma, do not delay filtration surgery 6
  • The AGIS trial showed that in advanced glaucoma, the lowest IOP group (47% reduction) had no further visual field deterioration 1
  • Trabeculectomy achieves 60% IOP reduction versus 38% with laser trabeculoplasty 1

Key Clinical Pitfalls

  1. Overestimating SLT efficacy in severe disease: Success rates decline with disease severity; early-stage PEX responds better than advanced cases 7

  2. Missing post-procedure IOP spikes: The heavily pigmented meshwork in PEX makes spikes more likely and potentially more damaging in severe glaucoma 1

  3. Delaying definitive surgery: If target IOP requires >50% reduction from baseline, proceed directly to trabeculectomy rather than attempting SLT first 6

  4. Inadequate treatment extent: 360-degree treatment is necessary for optimal results; 90-180 degree treatment is inferior to medical therapy 1

  5. Premature medication reduction: Maintain full medical therapy until sustained IOP control is documented over multiple visits

Repeat SLT Considerations

Repeat SLT can be performed if initial treatment loses effectiveness 1, though success rates may be lower than initial treatment. In severe PEX glaucoma, if repeat SLT is needed within 12 months, strongly consider proceeding to filtration surgery instead, as this suggests inadequate response to laser therapy.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.